Literature DB >> 23713495

Amyloid fibrils containing fragmented ATTR may be the standard fibril composition in ATTR amyloidosis.

Elisabet Ihse1, Claudio Rapezzi, Giampaolo Merlini, Merrill D Benson, Yukio Ando, Ole B Suhr, Shu-Ichi Ikeda, Francesca Lavatelli, Laura Obici, Candida C Quarta, Ornella Leone, Hirofumi Jono, Mitsuharu Ueda, Massimiliano Lorenzini, Juris Liepnieks, Toshinori Ohshima, Masayoshi Tasaki, Taro Yamashita, Per Westermark.   

Abstract

Abstract The clinical phenotype of familial ATTR amyloidosis depends to some extent on the particular mutation, but differences exist also within mutations. We have previously described that two types of amyloid fibril compositions exist among Swedish ATTRV30M amyloidosis patients, one consisting of a mixture of intact and fragmented ATTR (type A) and one consisting of mainly intact ATTR (type B). The fibril types are correlated to phenotypic differences. Patients with ATTR fragments have a late onset and develop cardiomyopathy, while patients without fragments have an early onset and less myocardial involvement. The present study aimed to determine whether this correlation between fibril type and phenotype is valid for familial ATTR amyloidosis in general. Cardiac or adipose tissues from 63 patients carrying 29 different TTR non-V30M mutations as well as 13 Japanese ATTRV30M patients were examined. Fibril type was determined by western blotting and compared to the patients' age of onset and degree of cardiomyopathy. All ATTR non-V30M patients had a fibril composition with ATTR fragments, except two ATTRY114C patients. No clear conclusions could be drawn about a phenotype to fibril type correlation among ATTR non-V30M patients. In contrast, Japanese ATTRV30M patients showed a similar correlation as previously described for Swedish ATTRV30M patients. This study shows that a fibril composition with fragmented ATTR is very common in ATTR amyloidosis, and suggests that fibrils composed of only full-length ATTR is an exception found only in a subset of patients.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23713495     DOI: 10.3109/13506129.2013.797890

Source DB:  PubMed          Journal:  Amyloid        ISSN: 1350-6129            Impact factor:   7.141


  48 in total

1.  Amyloid seeding of transthyretin by ex vivo cardiac fibrils and its inhibition.

Authors:  Lorena Saelices; Kevin Chung; Ji H Lee; Whitaker Cohn; Julian P Whitelegge; Merrill D Benson; David S Eisenberg
Journal:  Proc Natl Acad Sci U S A       Date:  2018-06-28       Impact factor: 11.205

2.  Genetic and clinical characteristics of hereditary transthyretin amyloidosis in endemic and non-endemic areas: experience from a single-referral center in Japan.

Authors:  Taro Yamashita; Mitsuharu Ueda; Yohei Misumi; Teruaki Masuda; Toshiya Nomura; Masayoshi Tasaki; Kotaro Takamatsu; Keiko Sasada; Konen Obayashi; Hirotaka Matsui; Yukio Ando
Journal:  J Neurol       Date:  2017-11-24       Impact factor: 4.849

3.  Amyloid deposits derived from transthyretin in the ligamentum flavum as related to lumbar spinal canal stenosis.

Authors:  Akihiro Yanagisawa; Mitsuharu Ueda; Takanao Sueyoshi; Tatsuya Okada; Toru Fujimoto; Yasuhiro Ogi; Keisuke Kitagawa; Masayoshi Tasaki; Yohei Misumi; Toshinori Oshima; Hirofumi Jono; Konen Obayashi; Kei Hirakawa; Hitoshi Uchida; Per Westermark; Yukio Ando; Hiroshi Mizuta
Journal:  Mod Pathol       Date:  2014-09-05       Impact factor: 7.842

4.  Unusual duplication mutation in a surface loop of human transthyretin leads to an aggressive drug-resistant amyloid disease.

Authors:  Elena S Klimtchuk; Tatiana Prokaeva; Nicholas M Frame; Hassan A Abdullahi; Brian Spencer; Surendra Dasari; Haili Cui; John L Berk; Paul J Kurtin; Lawreen H Connors; Olga Gursky
Journal:  Proc Natl Acad Sci U S A       Date:  2018-06-25       Impact factor: 11.205

Review 5.  Transthyretin Cardiac Amyloidosis in Black Americans.

Authors:  Keyur B Shah; Anit K Mankad; Adam Castano; Olakunle O Akinboboye; Phillip B Duncan; Icilma V Fergus; Mathew S Maurer
Journal:  Circ Heart Fail       Date:  2016-06       Impact factor: 8.790

6.  Positron emission tomography (PET) utilizing Pittsburgh compound B (PIB) for detection of amyloid heart deposits in hereditary transthyretin amyloidosis (ATTR).

Authors:  Björn Pilebro; Sandra Arvidsson; Per Lindqvist; Torbjörn Sundström; Per Westermark; Gunnar Antoni; Ole Suhr; Jens Sörensen
Journal:  J Nucl Cardiol       Date:  2016-09-19       Impact factor: 5.952

Review 7.  Cardiac amyloidosis: the great pretender.

Authors:  Claudio Rapezzi; Massimiliano Lorenzini; Simone Longhi; Agnese Milandri; Christian Gagliardi; Ilaria Bartolomei; Fabrizio Salvi; Mathew S Maurer
Journal:  Heart Fail Rev       Date:  2015-03       Impact factor: 4.214

8.  Comparative study of the stabilities of synthetic in vitro and natural ex vivo transthyretin amyloid fibrils.

Authors:  Sara Raimondi; P Patrizia Mangione; Guglielmo Verona; Diana Canetti; Paola Nocerino; Loredana Marchese; Rebecca Piccarducci; Valentina Mondani; Giulia Faravelli; Graham W Taylor; Julian D Gillmore; Alessandra Corazza; Mark B Pepys; Sofia Giorgetti; Vittorio Bellotti
Journal:  J Biol Chem       Date:  2020-06-22       Impact factor: 5.157

9.  Efficient 1-Hour Technetium-99 m Pyrophosphate Imaging Protocol for the Diagnosis of Transthyretin Cardiac Amyloidosis.

Authors:  Ahmad Masri; Syed Bukhari; Shahzad Ahmad; Ricardo Nieves; Yvonne S Eisele; William Follansbee; Amy Brownell; Timothy C Wong; Erik Schelbert; Prem Soman
Journal:  Circ Cardiovasc Imaging       Date:  2020-02-17       Impact factor: 7.792

10.  (11)C and (18)F Radiolabeling of Tetra- and Pentathiophenes as PET-Ligands for Amyloid Protein Aggregates.

Authors:  Patrik Nordeman; Leif B G Johansson; Marcus Bäck; Sergio Estrada; Håkan Hall; Daniel Sjölander; Gunilla T Westermark; Per Westermark; Lars Nilsson; Per Hammarström; K Peter R Nilsson; Gunnar Antoni
Journal:  ACS Med Chem Lett       Date:  2016-02-18       Impact factor: 4.345

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.